tldrdailynews.com logo

New Pancreatic Cancer Drug Daraxonrasib Delivers Landmark Phase 3 Results

1 min read
Source: CNBC
New Pancreatic Cancer Drug Daraxonrasib Delivers Landmark Phase 3 Results
Photo: CNBC
TL;DR

Revolution Medicines announced that its pancreatic cancer drug daraxonrasib met all primary and secondary endpoints in a Phase 3 trial, nearly doubling median overall survival (13.2 months vs 6.7 months) and reducing the risk of death by about 60% versus chemotherapy, prompting an FDA filing using a Commissioner’s National Priority Voucher; safety was manageable and the company is pursuing second-line use and trials in newly diagnosed patients.

Topics:businesshealth#daraxonrasib#health#overall-survival#pancreatic-cancer#phase-3-trial#revolution-medicines
Share this article
  1. Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial  CNBC
  2. RevMed’s Cancer Drug Nearly Doubles Overall Survival in Pivotal Study  Bloomberg.com
  3. Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial  Fierce Biotech
  4. Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill  statnews.com
  5. Daraxonrasib Demonstrates Unprecedented Overall Survival  GlobeNewswire

Want the full story? Read the original reporting

Read on CNBC